Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 74,846 shares, a decline of 83.8% from the August 31st total of 461,661 shares. Based on an average trading volume of 184,597 shares, the days-to-cover ratio is presently 0.4 days. Currently, 10.6% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

AEMD has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a report on Friday, July 17th. HC Wainwright restated a “neutral” rating on shares of Aethlon Medical in a research report on Friday, September 18th. Finally, Wall Street Zen raised shares of Aethlon Medical to a “sell” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aethlon Medical presently has an average rating of “Reduce” and a consensus target price of $1.50.

Aethlon Medical Trading Down 0.6%

Shares of NASDAQ:AEMD opened at $6.77 on Friday. The company has a market cap of $4.81 million, a price-to-earnings ratio of -0.19 and a beta of 1.40. Aethlon Medical has a 12 month low of $1.41 and a 12 month high of $41.35. The company has a 50-day moving average price of $3.04 and a 200 day moving average price of $7.19.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share for the quarter, missing the consensus estimate of ($3.92) by ($0.10). As a group, equities analysts forecast that Aethlon Medical will post -5.74 EPS for the current year.

About Aethlon Medical

Aethlon Medical, Inc is a clinical-stage medical device company focused on developing therapeutic technologies for cancer and life-threatening viral infections. The company’s lead product is the Hemopurifier, an investigational extracorporeal blood filtration device designed to selectively remove certain disease-causing particles, including tumor-derived exosomes and viruses, from the bloodstream.

The Hemopurifier is being evaluated as a potential adjunct to existing treatments. In oncology, the technology is intended to remove exosomes that may contribute to tumor progression and immune suppression.